Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Breast CancerHyperinsulinismHER2-negative Breast Cancer

Interventions

DRUG

Dapagliflozin 10mg

10 mg tablets for oral administration daily throughout chemotherapy treatment

Trial Locations (1)

RECRUITING

Yale Cancer Center Smilow Cancer Hospital, New Haven

All Listed Sponsors

lead

Yale University

OTHER